Visual summary
Airway swelling, symptomatic electrolyte problems, and hemodynamic instability require distinct escalation pathways; preserve useful therapy through coordinated monitoring.
Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.
Diagram description
Connect symptoms to the pathway and the response. RAAS blockade — Blood pressure and filtration-pressure effects; Potassium handling — Check relevant laboratory context; Dizziness or palpitations — Assess physiology and escalate appropriately; Face / throat swelling — Emergency airway assessment. The exercise-session response depends on the symptom; these are not equivalent adverse effects. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.
Text version
Identify the exact pathway drug
ACE inhibitor, ARB, and sacubitril/valsartan can improve important cardiac/kidney outcomes while lowering BP and changing potassium or filtration. Record the agent and recent change; “a BP pill” does not identify its transition risks or monitoring needs.
Lip, tongue, or throat swelling
Possible angioedema is an airway concern. Stop activity and activate urgent assessment; tongue/throat symptoms or breathing difficulty require emergency response. Do not dismiss delayed angioedema because the ACE inhibitor has been used for years.
Palpitations or a concerning potassium result
Pause exertion and arrange timely medical evaluation, especially with weakness, syncope, ECG concerns, or severe hyperkalemia. Potassium elevation may be silent. Exercise tolerance and a normal appearance do not substitute for the ordered laboratory follow-up.
Dizziness: assess physiology
Measure BP/pulse and postural response when appropriate; review poor intake, vomiting/diarrhea, diuretics, NSAIDs, and congestion symptoms. Persistent symptomatic hypotension or new oliguria needs prescriber assessment rather than advice to push through the exercise.
Know the transition safeguard
An ACE inhibitor and sacubitril/valsartan require at least 36 hours separation in either direction. ARNI already contains an ARB, so avoid duplicate ARB therapy. Confirm the written stop/start plan and report discrepancies to the prescribing team.
Close the safety loop
Give the prescriber drug names, last doses, symptom timing, vitals, and available creatinine/potassium results. Review potassium-containing salt substitutes and pregnancy questions through the clinical team. Resume exercise after stabilization under the revised plan, not after an unsupervised medication experiment.
